Objective: joint application of recombinant human epidermal growth factor and basic fibroblast growth factor, to explore the impact of diabetic wound healing process.
 
:    Select 2001-05/2005-03 Guangxi Medical University, Burns and Plastic Surgery Rehabilitation Center treated 29 patients with diabetic foot ulcers in patients voluntarily signed informed consent. Random table, 29 patients were randomly divided into four groups: seven cases of the combined treatment group, eight cases of recombinant human epidermal growth factor group, basic fibroblast growth factor group of 6 patients, saline control group of eight cases. Groups of patients in the treatment record before the fasting blood glucose control 11.1mmol / L, with infection after effective antibiotics intravenously to infection control, wound curettage pathologic granulation. Combination group were given topical recombinant human epidermal growth factor 1500IU / Spraying the basic fibroblast growth factor 720AU /; recombinant human epidermal growth factor group treated with topical recombinant human epidermal growth factor 1500IU /; basic fibroblast The growth factor group was given outside the spray 720AU / basic fibroblast growth factor; saline control group only saline wipe the wound. Each group dressing the next day dressing, 3, 7 and 14 days after treatment wound epithelial Portuguese line and the maturity of the granulation tissue of wound.
 
       Results: The selection of the 29 cases of patients with diabetic foot, all the analysis of results. ① different times after wound treatment groups wound healing rate comparison: three days after wound treatment groups basically similar (P) 0.05); wound treatment seven days compared with the saline control group, the combined treatment group and recombinant human epidermal growth factor group significantly increased (P <0.05>; 14 days after the treatment of the wound with saline control group, the combined treatment group, recombinant human epidermal growth factor group, basic fibroblast growth factor group were significantly improved (21.67 ± 1.53)%, (33.50 ± 1.56)%, (28.77 ± 1.50)%, (23.73 ± 1.20)% (P <0.01 or 0.05 liter to the combination therapy group high most obvious ② wound treatment after different times granulation tissue growth and general observation of the situation: each group 3,7 days growth of granulation tissue in wound management are basically similar to (P) 0.05). wound management 14 days, the combined treatment group wound granulation tissue growth was significantly superior to recombinant human epidermal growth factor group, basic fibroblast growth factor group, saline control group (P <0.05>.